title: [MMF and CyA in the prevention of early acute rejection after renal transplantation].
abstract: OBJECTIVE
  To investigate the effect of MMF and low dose CyA on the prevention of early acute rejection after renal transplantation.
  
  
  METHODS
  146 patients with kidney transplantation were analyzed retrospectively from December 1997 to January 1999. These patients were divided into two groups according to the immunosuppressive regimen: Aza group (78 patients) and MMF group (68 patients). All patients met the following criteria: HLA mismatch </= 3 loci, lymphocytes toxicity test < 10%, PRA < 20% for second or third transplantation, warm ischemia time 5-11 minutes, and cold ischemia time 3-24 hours.
  
  
  RESULTS
  There were 24 patients with acute rejection episodes (30.77%) in the Aza group; and 10 patients (14.71%) in the MMF group, (P < 0.05). The dosage of CyA and blood concentration of CyA were significantly different; 6.00 +/- 1.21 mg x kg(-1) x d(-1) and 286.00 +/- 20.02 microg/L in the Aza group; 4.00 +/- 1.14 mg x kg(-1) x d(-1) and 204.00 +/- 20.18 microg/L in the MMF group (P < 0.001).
  
  
  CONCLUSIONS
  MMF with low dose CyA based triple regimen could prevent the acute rejection episodes effectively at the early period of post transplantation. This triple regimen can reduce the acute rejection episodes by 50%. To some extent, low dose CyA may avoid nephrotoxicity. The long-term effect of this regimen on allograft is still needed to observe.
authors.affiliation: Department of Urology, Beijing Red Cross Chaoyang Hospital, Capital University of Medical Sciences, Beijing 100020, China.
authors.forename: B
authors.initials: B
authors.lastname: He
authors.forename: X
authors.initials: X
authors.lastname: Han
authors.forename: J
authors.initials: J
authors.lastname: Liu
authors.forename: Z
authors.initials: Z
authors.lastname: Han
authors.forename: D
authors.initials: D
authors.lastname: Guan
authors.forename: J
authors.initials: J
authors.lastname: Gao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid